PacBio replaces CEO, plans layoffs of 8% of workforce in restructuring

What happened

Pacific Biosciences of California (PACB), a maker of gene-sequencing instruments, announced on August 5, 2026, a series of leadership and cost-cutting moves. The company reported its second-quarter financial results, appointed a new chief executive, and disclosed a restructuring plan that includes laying off about 40 employees, or roughly 8% of its workforce.

The stock closed at $1.19 on the announcement day, up 1.7% from the prior close of $1.17.

CEO change and transition

Mark Van Oene, 54, was appointed President and Chief Executive Officer and joined the board, effective August 5. He replaces Christian Henry, who stepped down as CEO on the same date but remains on the board and will serve as Senior Business Advisor through December 31, 2026, according to an 8-K filed with the SEC.

Van Oene's employment agreement provides an annual base salary of $743,000, a target bonus of 100% of his base salary, and initial equity awards worth about $2.25 million in total — a stock option and restricted stock units vesting over three years. He also receives a change-in-control severance agreement that increases his cash severance from 12 to 18 months of base salary if he is terminated without cause or resigns for good reason in connection with a change in control.

Henry, under a Transition Agreement, will receive a monthly salary of about $12,908 during his advisory role, continued vesting of outstanding equity, and a potential lump-sum payment of roughly $1.16 million after he signs a separation agreement following the end of his employment. He is not eligible for a 2026 cash bonus unless the transition period is extended by mutual agreement.

Restructuring and workforce reduction

On July 30, 2026, the board approved a restructuring plan that includes a reduction in force of approximately 40 employees. The company expects the cuts to be completed in the third quarter of 2026. Total pre-tax charges are estimated at about $2.0 million, mostly for severance, benefits, and outplacement services.

By the end of 2027, the company expects to reduce its annualized operating expenses by $30 million to $40 million through headcount and non-headcount cost actions. The filing states the restructuring is intended to 'better align the Company's organizational structure and resources with its strategic initiatives.'

Second-quarter financial results

The 8-K notes that the company issued a press release on August 5, 2026, announcing its financial results for the quarter ended June 30, 2026. The press release is attached as Exhibit 99.1 to the filing, but the specific numbers are not included in the provided filing text. Readers should refer to the full earnings release for revenue, earnings, and other metrics.

What this means

An 8-K is a current report that companies must file with the SEC to announce major events that shareholders should know about. Items 2.02 (results of operations), 2.05 (exit or disposal costs), and 5.02 (changes in directors or officers) are among the most common triggers for an 8-K.

Item 2.05 requires disclosure when a board approves a plan to dispose of a major asset or exit an activity. Here, the 'exit or disposal activity' is the reduction in force — a formal restructuring plan that creates identifiable costs. The filing itemizes the expected charges and headcount reduction so investors can understand the financial impact.

Item 5.02 covers changes in top executives. The company disclosed the departure of the former CEO, the appointment of a new CEO, the key terms of his employment contract, and the transition agreement with the outgoing CEO. These details let shareholders assess leadership continuity and the cost of the transition.

The restructuring is a cost-cutting move, not a liquidation or bankruptcy. Layoffs of 8% of the workforce, combined with a projected $30-$40 million in annual savings, suggest the company is trying to reduce cash burn and focus resources on its strategic priorities. PacBio's stock has traded below $2 per share for some time, reflecting investor concern about its financial performance. The CEO change and restructuring signal an attempt to turn the business around, but the filing does not explain why the prior strategy failed or what specific initiatives the new CEO will pursue.